Form 4: EXAGEN Director Frank Stokes Granted 9,000 Stock Options

EXAGEN Inc. Director Frank Stokes has been granted 9,000 stock options with an exercise price of $7.36, aligning his interests with shareholder value.

Summary

• Frank Stokes, a Director at EXAGEN INC. (XGN), was granted 9,000 stock options.
• The transaction date for the option grant was June 10, 2025.
• The exercise price for these stock options is $7.36 per share.
• The options are scheduled to expire on June 9, 2035.
• The 9,000 shares subject to this option will fully vest and become exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next annual meeting of the Issuer's stockholders.
• Vesting is contingent upon Mr. Stokes' continued service on the board of directors through the vesting date.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued alignment of a director's interests with the company's performance through equity compensation.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the company's stock price increases.
• The long expiration date (June 9, 2035) provides a significant window for the options to become in-the-money, indicating a long-term incentive for the director.

Future Outlook

The vesting schedule for the stock options, tied to either the first anniversary of the grant date or the next annual meeting, indicates an expectation of continued service from Director Frank Stokes on the board of directors.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically an equity grant, which is a common practice in publicly traded companies across various industries to compensate and incentivize directors and executives, aligning their financial interests with company performance.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be seen as a positive for shareholders as it aligns the director's financial incentives with the company's stock performance.
• Director (Frank Stokes): This grant represents a form of compensation and a long-term incentive for his continued service on the board.

Next Steps

• The stock options will vest on the first anniversary of the grant date (June 10, 2026) or at the next annual meeting of stockholders, whichever occurs first, provided the director continues his service.

Key Dates

Keywords

EXAGEN, XGN, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Grant, Corporate Governance